Market Closed -
Swiss Exchange
11:30:41 2024-05-31 am EDT
|
5-day change
|
1st Jan Change
|
93.06
CHF
|
+1.67%
|
|
+1.43%
|
+10.04%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
214,715
|
215,682
|
196,476
|
194,400
|
207,226
|
210,402
|
-
|
-
|
Enterprise Value (EV)
1 |
230,615
|
240,182
|
204,667
|
203,434
|
219,237
|
222,469
|
221,014
|
215,148
|
P/E ratio
|
30.4
x
|
26.7
x
|
8.2
x
|
28.3
x
|
14.1
x
|
20
x
|
17.3
x
|
16
x
|
Yield
|
3.19%
|
3.56%
|
3.83%
|
3.87%
|
3.79%
|
3.51%
|
3.64%
|
3.82%
|
Capitalization / Revenue
|
4.53
x
|
4.43
x
|
3.81
x
|
3.85
x
|
4.56
x
|
4.29
x
|
4.11
x
|
4.05
x
|
EV / Revenue
|
4.86
x
|
4.94
x
|
3.96
x
|
4.02
x
|
4.82
x
|
4.53
x
|
4.32
x
|
4.14
x
|
EV / EBITDA
|
14.6
x
|
14.3
x
|
11.2
x
|
10.9
x
|
12.2
x
|
11.5
x
|
10.6
x
|
10.1
x
|
EV / FCF
|
17.9
x
|
20.5
x
|
15.4
x
|
17
x
|
16.6
x
|
16.1
x
|
14.4
x
|
13.3
x
|
FCF Yield
|
5.58%
|
4.87%
|
6.49%
|
5.87%
|
6.01%
|
6.22%
|
6.96%
|
7.54%
|
Price to Book
|
3.87
x
|
3.78
x
|
2.9
x
|
3.23
x
|
4.42
x
|
4.57
x
|
4.52
x
|
4.23
x
|
Nbr of stocks (in thousands)
|
2,264,608
|
2,274,506
|
2,237,092
|
2,150,980
|
2,055,460
|
2,040,406
|
-
|
-
|
Reference price
2 |
94.81
|
94.83
|
87.83
|
90.38
|
100.8
|
103.1
|
103.1
|
103.1
|
Announcement Date
|
1/29/20
|
1/26/21
|
2/2/22
|
2/1/23
|
1/31/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
47,445
|
48,659
|
51,626
|
50,545
|
45,440
|
49,081
|
51,178
|
51,908
|
EBITDA
1 |
15,809
|
16,845
|
18,246
|
18,613
|
17,937
|
19,298
|
20,849
|
21,266
|
EBIT
1 |
14,112
|
15,416
|
16,588
|
16,665
|
16,372
|
18,187
|
19,323
|
19,678
|
Operating Margin
|
29.74%
|
31.68%
|
32.13%
|
32.97%
|
36.03%
|
37.05%
|
37.76%
|
37.91%
|
Earnings before Tax (EBT)
1 |
8,940
|
9,878
|
26,137
|
8,371
|
9,123
|
13,255
|
14,695
|
15,277
|
Net income
1 |
7,147
|
8,072
|
24,021
|
6,955
|
14,854
|
10,482
|
11,741
|
12,641
|
Net margin
|
15.06%
|
16.59%
|
46.53%
|
13.76%
|
32.69%
|
21.36%
|
22.94%
|
24.35%
|
EPS
2 |
3.120
|
3.550
|
10.71
|
3.190
|
7.150
|
5.151
|
5.977
|
6.457
|
Free Cash Flow
1 |
12,875
|
11,691
|
13,282
|
11,945
|
13,179
|
13,834
|
15,386
|
16,219
|
FCF margin
|
27.14%
|
24.03%
|
25.73%
|
23.63%
|
29%
|
28.19%
|
30.06%
|
31.25%
|
FCF Conversion (EBITDA)
|
81.44%
|
69.4%
|
72.79%
|
64.18%
|
73.47%
|
71.68%
|
73.79%
|
76.27%
|
FCF Conversion (Net income)
|
180.15%
|
144.83%
|
55.29%
|
171.75%
|
88.72%
|
131.98%
|
131.04%
|
128.31%
|
Dividend per Share
2 |
3.025
|
3.375
|
3.360
|
3.500
|
3.823
|
3.622
|
3.756
|
3.939
|
Announcement Date
|
1/29/20
|
1/26/21
|
2/2/22
|
2/1/23
|
1/31/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
13,229
|
12,531
|
12,781
|
12,543
|
12,690
|
12,953
|
13,622
|
11,782
|
11,423
|
11,829
|
12,257
|
12,470
|
12,667
|
12,260
|
12,510
|
EBITDA
|
4,274
|
4,407
|
4,989
|
4,783
|
4,473
|
-
|
4,668
|
-
|
4,224
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
3,819
|
4,083
|
4,270
|
4,282
|
4,030
|
4,413
|
4,668
|
4,405
|
3,821
|
4,537
|
4,623
|
4,750
|
4,543
|
4,980
|
4,920
|
Operating Margin
|
28.87%
|
32.58%
|
33.41%
|
34.14%
|
31.76%
|
34.07%
|
34.27%
|
37.39%
|
33.45%
|
38.35%
|
37.72%
|
38.09%
|
35.87%
|
40.62%
|
39.33%
|
Earnings before Tax (EBT)
1 |
16,951
|
2,669
|
2,042
|
1,919
|
1,741
|
2,740
|
2,769
|
1,552
|
2,377
|
3,129
|
3,856
|
3,879
|
3,664
|
-
|
-
|
Net income
1 |
16,308
|
2,222
|
1,695
|
1,575
|
1,466
|
2,293
|
2,316
|
1,513
|
8,480
|
2,688
|
2,777
|
2,814
|
2,515
|
-
|
-
|
Net margin
|
123.27%
|
17.73%
|
13.26%
|
12.56%
|
11.55%
|
17.7%
|
17%
|
12.84%
|
74.24%
|
22.72%
|
22.65%
|
22.56%
|
19.86%
|
-
|
-
|
EPS
2 |
7.290
|
1.000
|
0.7700
|
0.7300
|
0.6900
|
1.090
|
1.110
|
0.7300
|
4.140
|
1.310
|
1.358
|
1.386
|
1.252
|
-
|
-
|
Dividend per Share
2 |
3.360
|
-
|
-
|
-
|
3.500
|
-
|
-
|
-
|
3.823
|
-
|
0.9595
|
0.9595
|
0.9595
|
1.025
|
1.025
|
Announcement Date
|
2/2/22
|
4/26/22
|
7/19/22
|
10/25/22
|
2/1/23
|
4/25/23
|
7/18/23
|
10/24/23
|
1/31/24
|
4/23/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
15,900
|
24,500
|
8,191
|
9,034
|
12,011
|
12,067
|
10,612
|
4,745
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
1.006
x
|
1.454
x
|
0.4489
x
|
0.4854
x
|
0.6696
x
|
0.6253
x
|
0.509
x
|
0.2231
x
|
Free Cash Flow
1 |
12,875
|
11,691
|
13,282
|
11,945
|
13,179
|
13,834
|
15,386
|
16,219
|
ROE (net income / shareholders' equity)
|
17.5%
|
23.5%
|
22.7%
|
21%
|
25.4%
|
32.9%
|
38.5%
|
37.6%
|
ROA (Net income/ Total Assets)
|
8.89%
|
6.45%
|
10.9%
|
10.7%
|
12.4%
|
10.7%
|
12.8%
|
14.2%
|
Assets
1 |
80,393
|
125,215
|
221,201
|
64,915
|
120,082
|
97,523
|
91,739
|
88,933
|
Book Value Per Share
2 |
24.50
|
25.10
|
30.30
|
28.00
|
22.80
|
22.60
|
22.80
|
24.40
|
Cash Flow per Share
2 |
5.880
|
5.950
|
6.670
|
6.480
|
6.910
|
7.790
|
8.430
|
8.720
|
Capex
1 |
2,257
|
1,275
|
1,378
|
1,198
|
1,060
|
1,195
|
1,271
|
1,325
|
Capex / Sales
|
4.76%
|
2.62%
|
2.67%
|
2.37%
|
2.33%
|
2.43%
|
2.48%
|
2.55%
|
Announcement Date
|
1/29/20
|
1/26/21
|
2/2/22
|
2/1/23
|
1/31/24
|
-
|
-
|
-
|
Last Close Price
103.1
USD Average target price
108.8
USD Spread / Average Target +5.53% Consensus |
1st Jan change
|
Capi.
|
---|
| +40.73% | 739B | | +32.83% | 598B | | -6.30% | 353B | | +15.15% | 318B | | +4.05% | 285B | | +15.00% | 240B | | -5.52% | 206B | | +6.17% | 164B | | -0.45% | 162B |
Other Pharmaceuticals
|